NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 41 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $6,843 | +18.7% | 8,244 | +0.1% | 0.00% | – |
| Q1 2023 | $5,763 | +37.6% | 8,233 | +0.0% | 0.00% | – |
| Q4 2022 | $4,189 | -16.2% | 8,229 | +0.1% | 0.00% | – |
| Q3 2022 | $5,000 | -37.5% | 8,223 | +0.0% | 0.00% | – |
| Q2 2022 | $8,000 | -63.6% | 8,219 | -28.3% | 0.00% | – |
| Q1 2022 | $22,000 | -81.4% | 11,464 | -53.5% | 0.00% | – |
| Q4 2021 | $118,000 | +71.0% | 24,674 | +157.8% | 0.00% | – |
| Q3 2021 | $69,000 | -37.3% | 9,570 | -20.1% | 0.00% | – |
| Q2 2021 | $110,000 | -40.2% | 11,970 | -19.7% | 0.00% | – |
| Q1 2021 | $184,000 | -74.3% | 14,909 | -70.7% | 0.00% | – |
| Q4 2020 | $717,000 | +21.3% | 50,857 | +3.5% | 0.00% | – |
| Q3 2020 | $591,000 | -36.9% | 49,152 | -12.8% | 0.00% | – |
| Q2 2020 | $936,000 | +31100.0% | 56,335 | +23670.0% | 0.00% | – |
| Q1 2020 | $3,000 | – | 237 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,386,300 | $19,547,000 | 2.55% |
| EcoR1 Capital, LLC | 3,122,704 | $44,030,000 | 2.37% |
| Redmile Group, LLC | 4,131,869 | $58,259,000 | 0.70% |
| Boxer Capital, LLC | 1,501,058 | $21,165,000 | 0.68% |
| HighVista Strategies LLC | 69,727 | $983,000 | 0.63% |
| Baker Brothers Advisors | 3,821,740 | $53,887,000 | 0.20% |
| Highland Private Wealth Management | 93,998 | $1,326,000 | 0.12% |
| Sio Capital Management, LLC | 38,312 | $540,000 | 0.11% |
| Point72 Asset Management, L.P. | 1,195,725 | $16,860,000 | 0.08% |
| Granahan Investment Management | 246,299 | $3,473,000 | 0.08% |